Kenota Health develops a rapid allergy‑testing system that brings lab testing into the allergy specialist’s clinic, producing results in under 30 minutes from a few drops of blood via finger prick. The system is designed to allow physicians to test and treat more patients within a single clinic visit and to make pediatric sample collection faster and easier. Kenota aims to improve diagnosis speed and clarity for life‑threatening allergies and to support earlier access to immunotherapy. The company has consulted with the U.S. Food and Drug Administration from early development to align with regulatory needs. Kenota plans to use the new funding to complete development of its technology and begin the regulatory review process, with a market focus on the U.S. and Canada. Financially, the company raised a US$9M Series A and previously raised a US$2M seed round in 2016; it also won $25,000 in the 2014 Velocity Fund Finals.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2020